MannKind Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Michael Castagna
Chief executive officer
US$9.5m
Total compensation
| CEO salary percentage | 8.1% |
| CEO tenure | 8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
May 11
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
Mar 01MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Dec 17MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Oct 03MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 18
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Sep 12 Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$30m |
| Dec 31 2024 | US$9m | US$766k | US$28m |
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
Compensation vs Market: Michael's total compensation ($USD9.49M) is above average for companies of similar size in the US market ($USD6.18M).
Compensation vs Earnings: Michael's compensation has increased by more than 20% in the past year.
CEO
Michael Castagna (47 yo)
8yrs
Tenure
US$9,490,628
Compensation
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8yrs | US$9.49m | 0.74% $ 10.3m | |
| Chief Financial Officer | 1.1yrs | US$3.49m | no data | |
| Executive Vice President of Operations | 2.2yrs | US$2.97m | 0.035% $ 485.4k | |
| Executive VP | 23.3yrs | US$3.06m | 0.15% $ 2.1m | |
| Executive VP of Research & Development and Chief Medical Officer | 2yrs | US$2.96m | 0.064% $ 886.0k | |
| Executive Vice President of Technical Operations | 2.6yrs | US$1.12m | 0.031% $ 436.0k | |
| VP of Investor Relations & Treasury | 7.8yrs | US$519.59k | no data | |
| Executive Vice President of Human Resources | 8.4yrs | US$2.22m | 0.20% $ 2.7m | |
| Senior Vice President of Worldwide Regulatory Affairs | 19.6yrs | no data | no data | |
| Senior VP & Therapeutic Area Head of Endocrine Diseases | 2.3yrs | no data | no data | |
| President of Endocrine Business Unit | less than a year | no data | no data |
2.6yrs
Average Tenure
57.5yo
Average Age
Experienced Management: MNKD's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8yrs | US$9.49m | 0.74% $ 10.3m | |
| Independent Director | 21.6yrs | US$235.96k | 0.039% $ 540.2k | |
| Chairman Emeritus | less than a year | US$213.46k | 0.087% $ 1.2m | |
| Independent Director | 6.5yrs | US$220.96k | 0.0091% $ 126.3k | |
| Independent Director | 21.4yrs | US$210.96k | 0.0049% $ 68.2k | |
| Independent Director | 5.3yrs | US$235.96k | 0.058% $ 803.4k | |
| Independent Chairman | 10yrs | US$245.96k | 0.0080% $ 111.6k | |
| Independent Director | 4.4yrs | US$223.46k | 0.035% $ 488.1k | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Independent Director | less than a year | US$2.25m | 0.18% $ 2.5m | |
| Independent Director | 5.2yrs | US$225.96k | 0.036% $ 504.9k | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
5.3yrs
Average Tenure
64.5yo
Average Age
Experienced Board: MNKD's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 09:56 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MannKind Corporation is covered by 27 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |